デフォルト表紙
市場調査レポート
商品コード
959074

生物製剤の世界市場

Biologics

出版日: | 発行: Global Industry Analysts, Inc. | ページ情報: 英文 187 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.10円

ご注意:Single user licenseはDRM(デジタル著作権管理システム)付PDFとなります。
PDFの閲覧には Adobe Digital Editions (無償)のインストールが必要となります。
認証されたPC上のみでの閲覧と、1回のプリントアウトが可能となっております。

生物製剤の世界市場
出版日: 2021年04月01日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 187 Pages
納期: 即日から翌営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

世界の生物製剤の市場規模は、分析期間(2020年~2027年)に8.1%のCAGRで成長する見通しで、2020年の2,922億米ドルから2027年には5,056億米ドルに達すると予測されています。当レポートで分析されているセグメントの1つである治療用組換えタンパク質は、分析期間中に8.8%の年率で成長し、1,871億米ドルに達すると予測されています。

当レポートは、世界の生物製剤市場について調査しており、動向や見通し、成長要因、地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

調査対象企業の例

  • AbbVie, Inc.
  • Amgen, Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Janssen Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer, Inc.

目次

I. イントロダクション、調査手法、調査範囲

II. エグゼクティブサマリー

  • 市場概要
    • Covid-19の影響と迫り来る世界の景気後退
  • 主要企業
  • 動向と成長要因
  • 世界市場の見通し

III. 市場分析

  • 地域別市場分析
  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

IV. 競合

  • プロファイルされた企業の総数:43社
目次
Product Code: MCP16211

Abstract:

Global Biologics Market to Reach $505.6 Billion by 2027

Amid the COVID-19 crisis, the global market for Biologics estimated at US$292.2 Billion in the year 2020, is projected to reach a revised size of US$505.6 Billion by 2027, growing at a CAGR of 8.1% over the analysis period 2020-2027. Recombinant Therapeutic Proteins, one of the segments analyzed in the report, is projected to record a 8.8% CAGR and reach US$187.1 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Blood & Blood components segment is readjusted to a revised 7.5% CAGR for the next 7-year period.

The U.S. Market is Estimated at $86.5 Billion, While China is Forecast to Grow at 7.6% CAGR

The Biologics market in the U.S. is estimated at US$86.5 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$87.8 Billion by the year 2027 trailing a CAGR of 7.6% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.6% and 6.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 6.5% CAGR.

Cellular & Gene Therapy Segment to Record 6.1% CAGR

In the global Cellular & Gene Therapy segment, USA, Canada, Japan, China and Europe will drive the 6.1% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$48.3 Billion in the year 2020 will reach a projected size of US$73.3 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$58.2 Billion by the year 2027.

Select Competitors (Total 43 Featured) -

  • AbbVie, Inc.
  • Amgen, Inc.
  • AstraZeneca PLC
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Janssen Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Recombinant Therapeutic Proteins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Recombinant Therapeutic Proteins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Recombinant Therapeutic Proteins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Blood & Blood components by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Blood & Blood components by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Blood & Blood components by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Cellular & Gene Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Cellular & Gene Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Cellular & Gene Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 15: World 15-Year Perspective for Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 16: World Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 17: World Historic Review for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 18: World 15-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 19: World Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 20: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 21: World 15-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 22: World Current & Future Analysis for Autoimmune Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 23: World Historic Review for Autoimmune Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 24: World 15-Year Perspective for Autoimmune Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 25: World Current & Future Analysis for Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 26: World Historic Review for Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 27: World 15-Year Perspective for Diabetes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
    • TABLE 28: World Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 29: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 30: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 31: USA Current & Future Analysis for Biologics by Product Type - Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 32: USA Historic Review for Biologics by Product Type - Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 33: USA 15-Year Perspective for Biologics by Product Type - Percentage Breakdown of Value Sales for Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines for the Years 2012, 2020 & 2027
    • TABLE 34: USA Current & Future Analysis for Biologics by Application - Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 35: USA Historic Review for Biologics by Application - Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 36: USA 15-Year Perspective for Biologics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications for the Years 2012, 2020 & 2027
  • CANADA
    • TABLE 37: Canada Current & Future Analysis for Biologics by Product Type - Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 38: Canada Historic Review for Biologics by Product Type - Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 39: Canada 15-Year Perspective for Biologics by Product Type - Percentage Breakdown of Value Sales for Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines for the Years 2012, 2020 & 2027
    • TABLE 40: Canada Current & Future Analysis for Biologics by Application - Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 41: Canada Historic Review for Biologics by Application - Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 42: Canada 15-Year Perspective for Biologics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications for the Years 2012, 2020 & 2027
  • JAPAN
    • TABLE 43: Japan Current & Future Analysis for Biologics by Product Type - Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 44: Japan Historic Review for Biologics by Product Type - Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 45: Japan 15-Year Perspective for Biologics by Product Type - Percentage Breakdown of Value Sales for Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines for the Years 2012, 2020 & 2027
    • TABLE 46: Japan Current & Future Analysis for Biologics by Application - Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 47: Japan Historic Review for Biologics by Application - Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 48: Japan 15-Year Perspective for Biologics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications for the Years 2012, 2020 & 2027
  • CHINA
    • TABLE 49: China Current & Future Analysis for Biologics by Product Type - Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 50: China Historic Review for Biologics by Product Type - Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 51: China 15-Year Perspective for Biologics by Product Type - Percentage Breakdown of Value Sales for Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines for the Years 2012, 2020 & 2027
    • TABLE 52: China Current & Future Analysis for Biologics by Application - Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 53: China Historic Review for Biologics by Application - Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 54: China 15-Year Perspective for Biologics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications for the Years 2012, 2020 & 2027
  • EUROPE
    • TABLE 55: Europe Current & Future Analysis for Biologics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 56: Europe Historic Review for Biologics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 57: Europe 15-Year Perspective for Biologics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 58: Europe Current & Future Analysis for Biologics by Product Type - Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 59: Europe Historic Review for Biologics by Product Type - Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 60: Europe 15-Year Perspective for Biologics by Product Type - Percentage Breakdown of Value Sales for Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines for the Years 2012, 2020 & 2027
    • TABLE 61: Europe Current & Future Analysis for Biologics by Application - Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 62: Europe Historic Review for Biologics by Application - Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 63: Europe 15-Year Perspective for Biologics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 64: France Current & Future Analysis for Biologics by Product Type - Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 65: France Historic Review for Biologics by Product Type - Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 66: France 15-Year Perspective for Biologics by Product Type - Percentage Breakdown of Value Sales for Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines for the Years 2012, 2020 & 2027
    • TABLE 67: France Current & Future Analysis for Biologics by Application - Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 68: France Historic Review for Biologics by Application - Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 69: France 15-Year Perspective for Biologics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 70: Germany Current & Future Analysis for Biologics by Product Type - Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 71: Germany Historic Review for Biologics by Product Type - Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 72: Germany 15-Year Perspective for Biologics by Product Type - Percentage Breakdown of Value Sales for Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines for the Years 2012, 2020 & 2027
    • TABLE 73: Germany Current & Future Analysis for Biologics by Application - Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 74: Germany Historic Review for Biologics by Application - Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 75: Germany 15-Year Perspective for Biologics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 76: Italy Current & Future Analysis for Biologics by Product Type - Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 77: Italy Historic Review for Biologics by Product Type - Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 78: Italy 15-Year Perspective for Biologics by Product Type - Percentage Breakdown of Value Sales for Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines for the Years 2012, 2020 & 2027
    • TABLE 79: Italy Current & Future Analysis for Biologics by Application - Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 80: Italy Historic Review for Biologics by Application - Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 81: Italy 15-Year Perspective for Biologics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • TABLE 82: UK Current & Future Analysis for Biologics by Product Type - Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 83: UK Historic Review for Biologics by Product Type - Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 84: UK 15-Year Perspective for Biologics by Product Type - Percentage Breakdown of Value Sales for Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines for the Years 2012, 2020 & 2027
    • TABLE 85: UK Current & Future Analysis for Biologics by Application - Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 86: UK Historic Review for Biologics by Application - Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 87: UK 15-Year Perspective for Biologics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 88: Rest of Europe Current & Future Analysis for Biologics by Product Type - Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 89: Rest of Europe Historic Review for Biologics by Product Type - Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 90: Rest of Europe 15-Year Perspective for Biologics by Product Type - Percentage Breakdown of Value Sales for Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines for the Years 2012, 2020 & 2027
    • TABLE 91: Rest of Europe Current & Future Analysis for Biologics by Application - Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 92: Rest of Europe Historic Review for Biologics by Application - Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 93: Rest of Europe 15-Year Perspective for Biologics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 94: Asia-Pacific Current & Future Analysis for Biologics by Product Type - Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 95: Asia-Pacific Historic Review for Biologics by Product Type - Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 96: Asia-Pacific 15-Year Perspective for Biologics by Product Type - Percentage Breakdown of Value Sales for Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines for the Years 2012, 2020 & 2027
    • TABLE 97: Asia-Pacific Current & Future Analysis for Biologics by Application - Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 98: Asia-Pacific Historic Review for Biologics by Application - Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 99: Asia-Pacific 15-Year Perspective for Biologics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications for the Years 2012, 2020 & 2027
  • REST OF WORLD
    • TABLE 100: Rest of World Current & Future Analysis for Biologics by Product Type - Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 101: Rest of World Historic Review for Biologics by Product Type - Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 102: Rest of World 15-Year Perspective for Biologics by Product Type - Percentage Breakdown of Value Sales for Recombinant Therapeutic Proteins, Blood & Blood components, Cellular & Gene Therapy and Vaccines for the Years 2012, 2020 & 2027
    • TABLE 103: Rest of World Current & Future Analysis for Biologics by Application - Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 104: Rest of World Historic Review for Biologics by Application - Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 105: Rest of World 15-Year Perspective for Biologics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Autoimmune Diseases, Diabetes and Other Applications for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 43